Researchers at Brigham and Women’s Hospital in Boston have developed an implant, notably as small as a grain of rice, that can test the effects of drugs on a patient’s brain tumor in real-time during surgery. Currently, monitoring the effects of drugs on a brain cancer patient during surgery is limited to intraoperative brain imaging and tissue sampling after a drug has been administered.
Researchers at Northwestern University developed a bioelectric implant that can detect temperature fluctuations that typically happen right before a body rejects an organ transplant. The sensor is smaller than a fingernail, and a mere 220 micrometers thick.
Clearblue has launched a new product that can determine what stage of menopause a person is in. The "Menopause Stage Indicator" is a urine testing device and it's the company's first for this underserved market in women's health.
German Bionic, the robot exoskeleton startup behind the lightweight Apogee exosuit, just revealed the Apogee+, a hardware refresh intended to service health care workers. The powered exoskeleton allows nurses and other health care professionals to have greater access to patients, particularly the elderly and the infirm. The company hopes to decrease the “immense levels of stress endured” by these medical professionals.
Insider/Kai Xiang Teo
Dr. Tom Oxley visibly stiffens at the prospect of using brain-computer interface technology for something as gauche as augmenting able-bodied humans. “We're not building a BCI to control Spotify or to watch Netflix,” the CEO of medical device startup Synchron tersely told Engadget via videocall last week.
Thor
The Withings Body Scan Connected Health Station has received the go-ahead from the FDA and is set to launch this fall.
Jakub Porzycki/NurPhoto via Getty Images
CVS Health is launching a new subsidiary unit, Cordavis, that will collaborate with drug manufacturers to produce biosimilar products, or medications that are near identical to an already approved and existing drug. This unit will commercialize and co-produce FDA-approved biosimilar products to U.S. markets, which will likely have a trickle-down effect on the way consumers buy drugs by increasing competition and driving down prices.